COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
15/06/2026
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, [...]
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
15/06/2026
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 [...]
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
15/06/2026
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as [...]
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
15/06/2026
SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical [...]
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
15/06/2026
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+ [...]
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
15/06/2026
Integration supports remote patient monitoring and value-based care SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“ [...]
Fate Therapeutics Appoints Laura Hamill to Board of Directors
15/06/2026
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE [...]
Porosome Therapeutics Announces Global Drug Development Partnership with the Largest Governmental R&D Organization in India
15/06/2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Porosome Therapeutics, Inc., announced today that it has entered into a drug development partnership with the Council of Scientific and Industrial Research (CSIR) of the [...]
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
15/06/2026
Seasoned biopharma executive with extensive experience building and leading organizations and supporting therapeutic pipeline programs in psychiatry MORRISTOWN, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Reunion [...]
Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes
15/06/2026
More than 75% of patients screened show elevated cortisol level associated with increased prevalence of cardiovascular disease Inadequate glycemic control despite incretin mimetic use and concomitant hypertension were [...]
KFSH Highlights Provider Transformation Through Measurable Operational Impact at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is bringing a practical provider-transformation message during its participation at HLTH Europe 2026, taking [...]
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
15/06/2026
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a [...]
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
15/06/2026
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months [...]
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
15/06/2026
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today [...]
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel [...]
XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
15/06/2026
La demande d’IND pour l’étude V-SPINE a fait l’objet d’un examen de 30 jours par la FDA sans suspension clinique, ouvrant ainsi la voie au recrutement de patients aux États-Unis AUSTIN, Texas, 15 juin 2026 (GLOBE [...]
Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec
15/06/2026
VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
15/06/2026
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX’s platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including [...]
BVI Expands Commitment to Ophthalmic Education with New Experience Hub in Europe
15/06/2026
New facility expands opportunities for hands-on learning, professional development, and clinical collaboration. BVI plans to expand the Hub's educational offerings through structured programs covering cataract surgery, [...]

Pages